4.2 Article

HIV-1-specific antibody responses during acute and chronic HIV-1 infection

Journal

CURRENT OPINION IN HIV AND AIDS
Volume 4, Issue 5, Pages 373-379

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/COH.0b013e32832f00c0

Keywords

antibody; humoral responses; isotype; mucosal

Funding

  1. National Institutes of Health (NIH/NIAID) [RO1AI052779, U19AI067854, AI068618, PO1AI061734, PO1AI052816]
  2. Bill and Melinda Gates Foundation [38619, 38643, 38617]
  3. NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI067854, P30AI064518, UM1AI068618, U01AI068618, U19AI067854, P01AI061734, P01AI052816, R01AI052779, U01AI046725] Funding Source: NIH RePORTER

Ask authors/readers for more resources

Purpose of review The humoral immune response to HIV-1 throughout infection is comprised of complex mixtures of antibody isotypes with numerous HIV-1 specificities. However, unlike antibody responses to most infections, protective antibody responses are delayed and do not arise until long after HIV-1 latency is established. We review recent data on HIV-1-specific antibody isotypes induced following HIV-1 transmission: to understand the effects of HIV-1 on B cell and T cell effector responses, to understand the timing of the rise and fall of different anti-HIV-1 antibodies and to understand how antibodies could contribute to protective immunity if they were either pre-existing or elicited immediately after HIV-1 transmission. Recent findings Studies of the earliest events following infection by the transmitted/founder virus have recently revealed that early destruction of B cell generative microenvironments may be responsible for delay of potentially protective anti-HIV-1 antibody responses. Unlike the initial CD8(+) T cell response to HIV-1, the initial induced antibody response is usually ineffective in controlling virus replication during acute HIV-1 infection. Summary The antibody isotypes and specificities elicited during HIV-1 infection can provide a window into deciphering the detrimental effects of HIV-1 on B cell and T cell responses. Additionally, further characterization of the virus inhibitory capabilities of anti-HIV-1 antibody isotypes can define the spectrum of potential protective HIV-1 antibodies that could be readily elicited by experimental vaccines and adjuvants.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available